179 related articles for article (PubMed ID: 37455444)
1. Interval cancer after two rounds of a Swedish population-based screening program using gender-specific cut-off levels in fecal immunochemical test.
Ribbing Wilén H; Blom J
J Med Screen; 2024 Mar; 31(1):8-14. PubMed ID: 37455444
[TBL] [Abstract][Full Text] [Related]
2. Interval cancers in a population-based screening program for colorectal cancer with gender-specific cut-off levels for fecal immunochemical test.
Ribbing Wilén H; Saraste D; Blom J
J Med Screen; 2022 Sep; 29(3):156-165. PubMed ID: 35257615
[TBL] [Abstract][Full Text] [Related]
3. Gender-specific cut-off levels in colorectal cancer screening with fecal immunochemical test: A population-based study of colonoscopy findings and costs.
Ribbing Wilén H; Saraste D; Blom J
J Med Screen; 2021 Dec; 28(4):439-447. PubMed ID: 34106777
[TBL] [Abstract][Full Text] [Related]
4. Interval Colorectal Cancer Incidence Among Subjects Undergoing Multiple Rounds of Fecal Immunochemical Testing.
van der Vlugt M; Grobbee EJ; Bossuyt PMM; Bos A; Bongers E; Spijker W; Kuipers EJ; Lansdorp-Vogelaar I; Spaander MCW; Dekker E
Gastroenterology; 2017 Aug; 153(2):439-447.e2. PubMed ID: 28483499
[TBL] [Abstract][Full Text] [Related]
5. Interval cancers using a quantitative faecal immunochemical test (FIT) for haemoglobin when colonoscopy capacity is limited.
Digby J; Fraser CG; Carey FA; Lang J; Stanners G; Steele RJ
J Med Screen; 2016 Sep; 23(3):130-4. PubMed ID: 26589788
[TBL] [Abstract][Full Text] [Related]
6. The second round of the Dutch colorectal cancer screening program: Impact of an increased fecal immunochemical test cut-off level on yield of screening.
Kooyker AI; Toes-Zoutendijk E; Opstal-van Winden AWJ; Spaander MCW; Buskermolen M; van Vuuren HJ; Kuipers EJ; van Kemenade FJ; Ramakers C; Thomeer MGJ; Dekker E; Nagtegaal ID; de Koning HJ; van Leerdam ME; Lansdorp-Vogelaar I
Int J Cancer; 2020 Aug; 147(4):1098-1106. PubMed ID: 31853977
[TBL] [Abstract][Full Text] [Related]
7. Factors associated with interval colorectal cancer after negative FIT: Results of two screening rounds in the Dutch FIT-based CRC screening program.
Breekveldt ECH; Toes-Zoutendijk E; van de Schootbrugge-Vandermeer HJ; de Jonge L; Kooyker AI; Spaander MCW; van Vuuren AJ; van Kemenade FJ; Ramakers C; Dekker E; Nagtegaal ID; van Leerdam ME; Lansdorp-Vogelaar I
Int J Cancer; 2023 Apr; 152(8):1536-1546. PubMed ID: 36444504
[TBL] [Abstract][Full Text] [Related]
8. Fecal immunochemical test in colorectal cancer screening: Colonoscopy findings by different cut-off levels.
Ribbing Wilén H; Blom J; Höijer J; Hultcrantz R
J Gastroenterol Hepatol; 2019 Jan; 34(1):103-112. PubMed ID: 29968937
[TBL] [Abstract][Full Text] [Related]
9. Sensitivity of fecal immunochemical test and risk factors for interval colorectal cancer in a French population.
Canévet M; Pruvost-Couvreur M; Morvan M; Badic B; Brousse-Potocki J; Kermarrec T; Bouzeloc S; Nousbaum JB; Robaszkiewicz M; Reboux N; Quénéhervé L
Clin Res Hepatol Gastroenterol; 2023 Mar; 47(3):102093. PubMed ID: 36764389
[TBL] [Abstract][Full Text] [Related]
10. Gender-specific cut-offs in colorectal cancer screening with FIT: Increased compliance and equal positivity rate.
Blom J; Löwbeer C; Elfström KM; Sventelius M; Öhman D; Saraste D; Törnberg S
J Med Screen; 2019 Jun; 26(2):92-97. PubMed ID: 30336730
[TBL] [Abstract][Full Text] [Related]
11. Occurrence and characteristics of faecal immunochemical screen-detected cancers vs non-screen-detected cancers: Results from a Flemish colorectal cancer screening programme.
van de Veerdonk W; Hoeck S; Peeters M; Van Hal G; Francart J; De Brabander I
United European Gastroenterol J; 2020 Mar; 8(2):185-194. PubMed ID: 32213071
[TBL] [Abstract][Full Text] [Related]
12. Optimizing the colorectal cancer screening programme using faecal immunochemical test (FIT) in Flanders, Belgium from the "interval cancer" perspective.
Tran TN; Peeters M; Hoeck S; Van Hal G; Janssens S; De Schutter H
Br J Cancer; 2022 Apr; 126(7):1091-1099. PubMed ID: 35022524
[TBL] [Abstract][Full Text] [Related]
13. Fecal immunochemical test in cancer screening - colonoscopy outcome in FIT positives and negatives.
Ribbing Wilén H; Blom J; Höijer J; Andersson G; Löwbeer C; Hultcrantz R
Scand J Gastroenterol; 2019 Mar; 54(3):303-310. PubMed ID: 30907196
[No Abstract] [Full Text] [Related]
14. Incidence of Interval Colorectal Cancer After Negative Results From First-Round Fecal Immunochemical Screening Tests, by Cutoff Value and Participant Sex and Age.
Toes-Zoutendijk E; Kooyker AI; Dekker E; Spaander MCW; Opstal-van Winden AWJ; Ramakers C; Buskermolen M; van Vuuren AJ; Kuipers EJ; van Kemenade FJ; Velthuysen MF; Thomeer MGJ; van Veldhuizen H; van Ballegooijen M; Nagtegaal ID; de Koning HJ; van Leerdam ME; Lansdorp-Vogelaar I;
Clin Gastroenterol Hepatol; 2020 Jun; 18(7):1493-1500. PubMed ID: 31442598
[TBL] [Abstract][Full Text] [Related]
15. Long-term performance of colorectal cancerscreening programmes based on the faecal immunochemical test.
Zorzi M; Hassan C; Capodaglio G; Fedato C; Montaguti A; Turrin A; Rosano A; Monetti D; Stocco C; Baracco S; Russo F; Repici A; Rugge M
Gut; 2018 Dec; 67(12):2124-2130. PubMed ID: 29101260
[TBL] [Abstract][Full Text] [Related]
16. Colorectal Cancer Stage Distribution at First and Repeat Fecal Immunochemical Test Screening.
Kooyker A; de Jonge L; Toes-Zoutendijk E; Spaander M; van Vuuren H; Kuipers E; van Kemenade F; Ramakers C; Dekker E; Nagtegaal I; van Leerdam M; Lansdorp-Vogelaar I
Clin Gastroenterol Hepatol; 2023 Dec; 21(13):3424-3432.e2. PubMed ID: 37619823
[TBL] [Abstract][Full Text] [Related]
17. Faecal immunochemical tests versus colonoscopy for post-polypectomy surveillance: an accuracy, acceptability and economic study.
Atkin W; Cross AJ; Kralj-Hans I; MacRae E; Piggott C; Pearson S; Wooldrage K; Brown J; Lucas F; Prendergast A; Marchevsky N; Patel B; Pack K; Howe R; Skrobanski H; Kerrison R; Swart N; Snowball J; Duffy SW; Morris S; von Wagner C; Halloran S
Health Technol Assess; 2019 Jan; 23(1):1-84. PubMed ID: 30618357
[TBL] [Abstract][Full Text] [Related]
18. Results of Compliant Participation in Five Rounds of Fecal Immunochemical Test Screening for Colorectal Cancer.
Baldacchini F; Bucchi L; Giuliani O; Mancini S; Ravaioli A; Vattiato R; Giorgi Rossi P; Campari C; Canuti D; Di Felice E; Mezzetti F; Sassoli de Bianchi P; Ferretti S; Falcini F;
Clin Gastroenterol Hepatol; 2021 Nov; 19(11):2361-2369. PubMed ID: 32827723
[TBL] [Abstract][Full Text] [Related]
19. Piloting gender-oriented colorectal cancer screening with a faecal immunochemical test: population-based registry study from Finland.
Sarkeala T; Färkkilä M; Anttila A; Hyöty M; Kairaluoma M; Rautio T; Voutilainen M; Helander S; Jäntti M; Lehtinen M; Patrikka L; Malila N; Heinävaara S
BMJ Open; 2021 Feb; 11(2):e046667. PubMed ID: 33558363
[TBL] [Abstract][Full Text] [Related]
20. Fecal Immunochemical Test Program Performance Over 4 Rounds of Annual Screening: A Retrospective Cohort Study.
Jensen CD; Corley DA; Quinn VP; Doubeni CA; Zauber AG; Lee JK; Zhao WK; Marks AR; Schottinger JE; Ghai NR; Lee AT; Contreras R; Klabunde CN; Quesenberry CP; Levin TR; Mysliwiec PA
Ann Intern Med; 2016 Apr; 164(7):456-63. PubMed ID: 26811150
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
